← Human Trials & Peer-Reviewed Studies
Glucagon use for esophageal coin dislodgment in children: a prospective, double-blind, placebo-controlled trial
Plain-language guide to PMID 11157302 (2001): double-blind randomized controlled trial study of Glucagon.
Key Facts
- PMID
- 11157302
- Journal
- Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Mehta D et al. (4 authors)
- DOI
- 10.1111/j.1553-2712.2001.tb01291.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glucagon, published as a randomized controlled trial.
Prospective evaluation of the use of glucagon in dislodgment of impacted esophageal coins in children.
Who Took Part
PubMed indexes the participants as infants, young children and children.
This was a double-blind, placebo-controlled study with an open-label second phase in children 1 to 8 years of age who presented to a pediatric emergency department with a radiographically confirmed single esophageal coin impaction.
Patients were placed in an upright position and asked to drink 2-3 ounces of water.
How the Study Was Run
In design terms this was a randomized, double-blind, open-label and placebo-controlled study.
Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Glucagon.
Being open-label, the Glucagon study did not mask who received what.
Some participants received a placebo instead of Glucagon, giving a reference point.
One milligram of glucagon or placebo was given intravenously in double-blinded fashion.
A repeat radiograph was obtained to check coin position in 30-60 minutes.
The glucagon and placebo groups were compared.
What Was Measured
PubMed files the paper under topics including Esophagus, Foreign Bodies, Gastrointestinal Agents, Glucagon and Muscle Relaxation.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Glucagon.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2001 (Academic emergency medicine : official journal of the Society for Academic Emergency Medicine), a journal based in United States.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.